Anal condylomas: predictors of recurrence and progression to high-grade dysplasia / carcinoma in situ

2016 ◽  
Author(s):  
Armando Peixoto
Keyword(s):  
Carcinoma In Situ ◽  
High Grade Dysplasia ◽  
High Grade ◽  
Predictors Of Recurrence

scholarly journals Anal condylomas: predictors of recurrence and progression to high-grade dysplasia/carcinoma in situ

2017 ◽  
Vol 8 (6) ◽  
pp. 1114-1115 ◽  
Author(s):  
Armando Peixoto ◽  
Marco Silva ◽  
Rui Castro ◽  
Rosa Coelho ◽  
Alexandre Sarmento ◽  
...  
Keyword(s):  
Carcinoma In Situ ◽  
High Grade Dysplasia ◽  
High Grade ◽  
Predictors Of Recurrence

scholarly journals Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Qiao Ke ◽  
Bin Wang ◽  
Nanping Lin ◽  
Lei Wang ◽  
Jingfeng Liu
Keyword(s):  
Local Recurrence ◽  
Carcinoma In Situ ◽  
Meta Analysis ◽  
Surgical Margin ◽  
High Grade Dysplasia ◽  
Cochrane Library ◽  
Biliary Duct ◽  
High Grade ◽  
Extrahepatic Cholangiocarcinoma

Abstract Background High-grade dysplasia/carcinoma in situ (HGD/CIS) of the biliary duct margin was found to not affect the prognosis of patients with extrahepatic cholangiocarcinoma by recent studies, but it has not yet reached a conclusion. Methods Eligible studies were searched by PubMed, PMC, MedLine, Embase, the Cochrane Library, and Web of Science, from Jan. 1, 2000 to Jun. 30, 2019, investigating the influences of surgical margin status of biliary duct on the prognosis of patients with resectable extrahepatic cholangiocarcinoma. Overall survival (OS) and local recurrence were evaluated by odds ratio (OR) with 95% confidence interval (CI). Results A total of 11 studies were enrolled in this meta-analysis, including 1734 patients in the R0 group, 194 patients in the HGD/CIS group, and 229 patients in the invasive carcinoma (INV) group. The pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and R0 group was 0.98 (95% CI 0.65~1.50), 1.01 (95% CI 0.73~1.41), and 0.98 (95% CI 0.72~1.34), respectively. The pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and INV group was 1.83 (95% CI 1.09~3.06), 4.52 (95% CI 2.20~9.26), and 3.74 (95% CI 2.34~5.96), respectively. Subgroup analysis of extrahepatic cholangiocarcinoma at early stage showed that the pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and R0 group was 0.54 (95% CI 0.21~1.36), 0.75 (95% CI 0.35~1.58), and 0.74 (95% CI 0.40~1.37), respectively, and the pooled OR for the 1-, 2-, and 3-year OS rate between HGD/CIS group and INV group was 3.47 (95% CI 1.09~11.02), 9.12 (95% CI 2.98~27.93), and 9.17 (95% CI 2.95~28.55), respectively. However, the pooled OR for the incidence of local recurrence between HGD/CIS group and R0 group was 3.54 (95% CI 1.66~7.53), and the pooled OR for the incidence of local recurrence between HGD/CIS group and INV group was 0.93 (95% CI 0.50~1.74). Conclusion With the current data, we concluded that HGD/CIS would increase the risk of local recurrence compared with R0, although it did not affect the prognosis of patients with extrahepatic cholangiocarcinoma regardless of TNM stage. However, the conclusion needs to be furtherly confirmed.

Diagnostic significance of narrow-band imaging for detecting high-grade dysplasia, carcinoma in situ, and carcinoma in oral leukoplakia

2012 ◽  
Vol 122 (12) ◽  
pp. 2754-2761 ◽  
Author(s):  
Shih-Wei Yang ◽  
Yun-Shien Lee ◽  
Liang-Che Chang ◽  
Cheng-Cheng Hwang ◽  
Tai-An Chen
Keyword(s):  
Carcinoma In Situ ◽  
Narrow Band ◽  
Narrow Band Imaging ◽  
Oral Leukoplakia ◽  
High Grade Dysplasia ◽  
High Grade ◽  
Diagnostic Significance

scholarly journals Mo1282 ADHERENCE TO RECOMMENDED SURVEILLANCE INTERVALS IS CHALLENGING FOR BARRETT'S ESOPHAGUS PATIENTS WITH HIGH-GRADE DYSPLASIA AND CARCINOMA IN-SITU

2020 ◽  
Vol 91 (6) ◽  
pp. AB415
Author(s):  
Phoebe S. Um ◽  
Megan Q. Chan ◽  
Alice Hinton ◽  
Sebastian Strobel ◽  
Kelly Haisley ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Carcinoma In Situ ◽  
High Grade Dysplasia ◽  
High Grade

Adenomas of the gallbladder. Morphologic features, expression of gastric and intestinal mucins, and incidence of high-grade dysplasia/carcinoma in situ and invasive carcinoma

2012 ◽  
Vol 43 (9) ◽  
pp. 1506-1513 ◽  
Author(s):  
Jorge Albores-Saavedra ◽  
Fredy Chablé-Montero ◽  
Marco Aurelio González-Romo ◽  
Manuel Ramírez Jaramillo ◽  
Donald E. Henson
Keyword(s):  
Carcinoma In Situ ◽  
Invasive Carcinoma ◽  
High Grade Dysplasia ◽  
High Grade ◽  
Intestinal Mucins

p53 Mutation Analysis of Low-Grade Dysplasia and High-Grade Dysplasia/Carcinoma in situ of the Esophagus Using Laser Capture Microdissection

Oncology ◽  
2006 ◽  
Vol 71 (3-4) ◽  
pp. 237-245 ◽  
Author(s):  
Maki Kobayashi ◽  
Hiroshi Kawachi ◽  
Toichiro Takizawa ◽  
Keisuke Uchida ◽  
Masaki Sekine ◽  
...  
Keyword(s):  
Mutation Analysis ◽  
Laser Capture Microdissection ◽  
Carcinoma In Situ ◽  
P53 Mutation ◽  
High Grade Dysplasia ◽  
Low Grade ◽  
High Grade ◽  
Low Grade Dysplasia ◽  
Laser Capture

scholarly journals Expression of Semaphorin 3A in Malignant and Normal Bladder Tissue: Immunohistochemistry Staining and Morphometric Evaluation

Biology ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 109
Author(s):  
Ilan Bejar ◽  
Jacob Rubinstein ◽  
Jacob Bejar ◽  
Edmond Sabo ◽  
Hilla K Sheffer ◽  
...  
Keyword(s):  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
Urothelial Cancer ◽  
Basal Layer ◽  
Low Grade ◽  
High Grade ◽  
Bladder Tissue ◽  
Normal Bladder ◽  
Normal Bladder Tissue

Introduction: Our previous studies showed elevated levels of Semaphorin3a (Sema3A) in the urine of patients with urothelial cancer compared to healthy patients. The aim of this study was to analyze the extent of Sema3A expression in normal and malignant urothelial tissue using immune-staining microscopic and morphometric analysis. Materials and Methods: Fifty-seven paraffin-embedded bladder samples were retrieved from our pathology archive and analyzed: 14 samples of normal urothelium, 21 samples containing low-grade urothelial carcinoma, 13 samples of patients with high-grade urothelial carcinoma, 7 samples containing muscle invasive urothelial carcinoma, and 2 samples with pure urothelial carcinoma in situ. All samples were immunostained with anti Sema3A antibodies. The area of tissue stained with Sema3A and its intensity were analyzed using computerized morphometry and compared between the samples’ groups. Results: In normal bladder tissue, very light Sema3A staining was demonstrated on the mucosal basal layer and completely disappeared on the apical layer. In low-grade tumor samples, cells in the basal layer of the mucosa were also lightly stained with Sema3A, but Seama3A expression intensified upon moving apically, reaching its highest level on apical cells exfoliating to the urine. In high grade urothelial tumors, Seama3A staining was intense in the entire thickness of the mucosa. In samples containing carcinoma in situ, staining intensity was high and homogenous in all the neoplastic cells. Conclusions: Sema3A may be serve as a potential non-invasive marker of urothelial cancer.

scholarly journals Patterns of invasive recurrence among patients originally treated for ductal carcinoma in situ by breast-conserving surgery versus mastectomy

2021 ◽  
Vol 186 (3) ◽  
pp. 617-624
Author(s):  
Kate R. Pawloski ◽  
Audree B. Tadros ◽  
Varadan Sevilimedu ◽  
Ashley Newman ◽  
Lori Gentile ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Advanced Disease ◽  
Breast Conserving Surgery ◽  
Risk Profile ◽  
High Grade ◽  
Group A ◽  
First Recurrence

Abstract Purpose Local recurrence after treatment of ductal carcinoma in situ (DCIS) with breast-conserving surgery (BCS) is more common than after mastectomy, but it is unclear if patterns of invasive recurrence vary by initial surgical therapy. Among patients with invasive recurrence after treatment for DCIS, we compared patterns of first recurrence between those originally treated with BCS vs. mastectomy. Methods From 2000 to 2016, women with an invasive recurrence occurring ≥ 6 months after initial treatment for DCIS were retrospectively identified. Clinicopathologic features and adjuvant treatment of the initial DCIS, as well as characteristics of first invasive recurrences, were compared between patients who had undergone BCS vs. mastectomy. Results 452 patients with an invasive recurrence after surgery for DCIS were identified: 367 patients (81%) had initially undergone BCS and 85 patients (19%) mastectomy. Patients originally treated with mastectomy were younger and were more likely to have had high grade, necrosis, and multifocal or multicentric DCIS (p < 0.001) compared with the BCS group. A higher proportion of invasive recurrences were local after BCS (93%; 343/367), whereas 88% (75/85) of recurrences after mastectomy were regional or distant (p < 0.001). The median time to first invasive recurrence was not different between surgical groups (BCS: 6.4 years vs. mastectomy: 5.5 years; p = 0.12). Conclusions Among women who experienced a first invasive recurrence after treatment for DCIS, those who had originally undergone mastectomy more commonly presented with advanced disease compared to those treated with BCS, likely related to the absence of the breast and the higher risk profile of their initial DCIS.

Sign in / Sign up

Export Citation Format

Share Document